DAVID LONARD to Bortezomib
This is a "connection" page, showing publications DAVID LONARD has written about Bortezomib.
Connection Strength
0.044
-
Targeting NSD2-mediated SRC-3 liquid-liquid phase separation sensitizes bortezomib treatment in multiple myeloma. Nat Commun. 2021 02 15; 12(1):1022.
Score: 0.044